Emiko Sano
University of Tokyo
26 Papers
123 Citations
Emiko Sano is an academic researcher from University of Tokyo. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 9, co-authored 23 publications.
Chat about Author
Papers
Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Atsuo Yoshino,Akiyoshi Ogino,Kazunari Yachi,Takashi Ohta,Takao Fukushima,Takao Watanabe,Yoichi Katayama,Yutaka Okamoto,Norio Naruse,Emiko Sano +9 more
TL;DR: The results suggest that the clinical therapeutic efficacy of TMZ might be improved by a combination with IFN-beta in malignant gliomas unmethylated at the MGMT gene, and provide an experimental basis for future strategies in TMZ chemotherapy.
48
Indoleamine 2,3-dioxygenase 1 is highly expressed in glioma stem cells
Yoshinari Ozawa,Shun Yamamuro,Emiko Sano,Juri Tatsuoka,Yuya Hanashima,Sodai Yoshimura,Koichiro Sumi,Hiroyuki Hara,Tomohiro Nakayama,Yutaka Suzuki,Atsuo Yoshino +10 more
TL;DR: GSCs exhibit treatment resistance with immunosuppression via high expression levels of IDO1, and could represent a novel target for GBM treatment, according to the immune systems of GSCs.
25
Contributions of Interfacial Residues of Human Interleukin15 to the Specificity and Affinity for Its Private α-Receptor
TL;DR: The thermodynamic basis of the recognition mechanism for its private alpha-receptor (hIL15Ralpha), considered the first step of the interleukin's activation pathway, is elucidated and a novel and critical role for residue Tyr26 in the interaction is unveiled, which facilitates desolvation of key charged residues during the assembly of the complex.
22
Efficacy of ribavirin against malignant glioma cell lines
Akiyoshi Ogino,Emiko Sano,Yushi Ochiai,Shun Yamamuro,Shinya Tashiro,Kazunari Yachi,Takashi Ohta,Takao Fukushima,Yutaka Okamoto,Kouhei Tsumoto,Takuya Ueda,Atsuo Yoshino,Yoichi Katayama +12 more
TL;DR: Cell cycle analysis of the U-87MG cell line demonstrated that ribavirin treatment induces G0/G1 arrest and thus may be an effective agent for inhibiting malignant glioma cell growth.
Interleukin-6 sensitizes TNF-α and TRAIL/Apo2L dependent cell death through upregulation of death receptors in human cancer cells.
Emiko Sano,Akira Kazaana,Hisashi Tadakuma,Toshiaki Takei,Sodai Yoshimura,Yuya Hanashima,Yoshinari Ozawa,Atsuo Yoshino,Yutaka Suzuki,Takuya Ueda +9 more
TL;DR: In this article, the effects of IL-6 using SKBR3 cells were associated with the generation of apoptotic cells as analyzed by fluorescence microscopy and flow cytometry.
16